Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Sci Total Environ ; 929: 172433, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38626824

ABSTRACT

Greenhouse gas emissions are significantly contributing to climate change, posing one of the serious threats to our planet. Addressing these emissions urgently is imperative to prevent irreversible planetary changes. One effective long-term mitigation strategy is achieving carbon neutrality. Although numerous countries aim for carbon neutrality by 2050, only a few are on track to realize this ambition. Existing technological solutions, including chemical absorption, cryogenic separation, and membrane separation, are available but tend to be costly and time intensive. Bio-capture methods present a promising opportunity in greenhouse gas mitigation research. Recent developments in biotechnology for capturing greenhouse gases have demonstrated both effectiveness and long-term benefits. This review emphasizes the recent advancements in bio-capture techniques, showcasing them as dependable and economical solutions for carbon neutrality. The article briefly outlines various bio-capture methods and underscores their potential for industrial application. Moreover, it investigates into the challenges faced when integrating bio-capture with carbon capture and storage technology. The study concludes by exploring the recent trends and prospective enhancements in ecosystem revitalization and industrial decarbonization through green conversion techniques, reinforcing the path towards carbon neutrality.

2.
Micromachines (Basel) ; 13(12)2022 Dec 12.
Article in English | MEDLINE | ID: mdl-36557500

ABSTRACT

Solar cells based on lead-free perovskite have demonstrated great potential for next-generation renewable energy. The SCAPS-1D simulation software was used in this study to perform novel device modelling of a lead-free perovskite solar cell of the architecture ITO/WS2/CH3NH3SnI3/P3HT/Au. For the performance evaluation, an optimization process of the different parameters such as thickness, bandgap, doping concentration, etc., was conducted. Extensive optimization of the thickness and doping density of the absorber and electron transport layer resulted in a maximum power-conversion efficiency of 33.46% for our designed solar cell. Because of the short diffusion length and higher defect density in thicker perovskite, an absorber thickness of 1.2 µm is recommended for optimal solar cell performance. Therefore, we expect that our findings will pave the way for the development of lead-free and highly effective perovskite solar cells.

3.
Front Public Health ; 10: 1000933, 2022.
Article in English | MEDLINE | ID: mdl-36330109

ABSTRACT

Background: From a demographic perspective, the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on life expectancy is not clear. Hence, there is a need to study the number of years of life lost concerning the existing average life expectancy due to COVID-19 in India. Objective: This study aimed to estimate the impact of life expectancy due to the COVID-19 pandemic in India. Methodology: We considered day-wise age-specific mortality due to COVID-19 which was extracted from the COVID-19 data repository from March 11, 2020, to June 30, 2021, in India. All-cause mortality was collected from the United Nations population estimates. An abridged life table technique was utilized for calculating life expectancies based on all-cause mortality and mortality due to COVID-19. MortPak software was used to calculate the life expectancy with and without the COVID-19 pandemic. Life expectancy at birth in different age groups was estimated with respect to with and without COVID-19. Results: A total of 399,459 deaths due to COVID-19 were distributed age wise, and their corresponding life expectancy was calculated. The general mortality was compared with COVID-19 mortality for the various age groups, and it was observed that mortality due to COVID-19 was significantly higher among the elderly age group [i.e., 45 to 60 years (36%) and > 60 years (51%)] when compared with < 25 years (1%) and 26-44 years (11%) (trend Chi-square 7.59; p = 0.001). The life expectancy without and with COVID-19 was 69.28 years and 69.16 years, respectively. Conclusion: Overall, it was estimated that COVID-19 has an impact on life expectancy by 0.12 years during the study period. Even though mortality due to COVID-19 was high, factors such as lockdown, vaccination, and accidents also had an influence on mortality. Thus, there is a need to assess the impact of COVID-19 on life expectancy in future.


Subject(s)
COVID-19 , Infant, Newborn , Humans , Aged , Middle Aged , COVID-19/epidemiology , Pandemics , SARS-CoV-2 , Communicable Disease Control , Life Expectancy , India/epidemiology
4.
J Public Health Policy ; 42(1): 185-189, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33235251

ABSTRACT

During the early months of the 2020 COVID-19 crisis, critical services in India for tuberculosis (TB) have been disrupted. India has one of the highest burdens of TB and requires continuity of critical TB care. Here, we highlight important points and approaches that can be used to guide navigation of the combined COVID-19 and TB crisis in India.


Subject(s)
COVID-19/epidemiology , Delivery of Health Care/organization & administration , Tuberculosis/epidemiology , Tuberculosis/therapy , Humans , India/epidemiology , Pandemics , SARS-CoV-2
5.
Microb Drug Resist ; 27(5): 647-651, 2021 May.
Article in English | MEDLINE | ID: mdl-32991238

ABSTRACT

Aim: This study aims to determine the frequency and pattern of gyrA/B mutations in multidrug-resistant (MDR) Mycobacterium tuberculosis (MTB) strains and also to assess the association between different gyrA/B mutations with phenotypic resistance to moxifloxacin (MOX) at clinical breakpoint (CB) drug concentration. Method: A total of 106 clinical MTB isolates carrying gyrA/B mutations were included consecutively. Culture-based MOX susceptibility was tested at CB (1.0 µg/mL) followed by its correlation with gyrA/B mutations using Genotype MTBDRsl assay. The mutations associated with phenotypic resistance were further analyzed on a large dataset of 1,825 MDR tuberculosis (TB) patients. Result: D94G and A90V mutations within gyrA were significantly associated with resistance and susceptible phenotype (p < 0.001), respectively. Of 1,825 MDR patients, gyrA/B mutations were found in 58.8% cases, of which fluoroquinolone (FQ) resistance was concluded among 97.9%, 0.8%, and 1.3% patients due to mutation in gyrA, gyrB, and in both the genes, respectively. D94G alone (45.9%) followed by A90V (21.2%) mutations in gyrA gene was most frequent. Conclusion: Our study showed that MDR-TB has emerged in northern India with additional FQ resistance. Different selection pressure and transmission may result in prevailing accumulation of specific gyrA mutations causing high-level FQ resistance, therefore, current control measures need to be strengthened.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antitubercular Agents/pharmacology , DNA Gyrase/genetics , Fluoroquinolones/pharmacology , Mycobacterium tuberculosis/drug effects , Tuberculosis, Multidrug-Resistant/genetics , Genes, Bacterial/genetics , Genotype , Humans , India/epidemiology , Microbial Sensitivity Tests , Moxifloxacin/pharmacology , Mutation , Mycobacterium tuberculosis/genetics , Phenotype
6.
J Glob Antimicrob Resist ; 24: 40-44, 2021 03.
Article in English | MEDLINE | ID: mdl-33279685

ABSTRACT

OBJECTIVES: Sputum culture conversion at the end of the intensive phase of multidrug-resistant tuberculosis (MDR-TB) treatment is a key predictor for successful treatment outcome. This observational study was undertaken to assess the interim microbiological outcome of a cohort of rifampicin-resistant (RR)-TB patients with variable resistance to second-line drugs. METHODS: During Jan-Apr 2018, we consecutively enrolled 100 RR-TB patients, who underwent phenotypic drug susceptibility testing (DST) to assess baseline resistance to second-line drugs. Following RR-TB diagnosis, these patients were started on MDR-TB treatment. After 6 months of treatment, sputum culture conversion status was determined. Data were analysed to assess the impact of resistance to second-line drugs on culture conversion. RESULTS: DST of 100 RR-TB patients showed a high resistance to fluoroquinolones (FQs; levofloxacin 56%; moxifloxacin 44%) followed by kanamycin (8%) and capreomycin (6%). None of the patients were resistant to the other drugs tested (amikacin, clofazimine and linezolid). At 6-month treatment follow-up, 28 patients had been lost to follow-up and eight had died. Microbiological outcome was obtained from the remaining 64 patients, but successful culture conversion was achieved in only 62.5% of the patients. FQ resistance was found to be a strong predictor (P<0.001) for unfavourable microbiological outcome. CONCLUSION: The rate of FQ resistance in RR/MDR-TB is high and has strong association with unsuccessful interim microbiological outcome of conventional MDR-TB treatment.


Subject(s)
Mycobacterium tuberculosis , Tuberculosis, Multidrug-Resistant , Antitubercular Agents/pharmacology , Antitubercular Agents/therapeutic use , Drug Resistance , Humans , Microbial Sensitivity Tests , Tuberculosis, Multidrug-Resistant/drug therapy
7.
Micromachines (Basel) ; 11(8)2020 Aug 15.
Article in English | MEDLINE | ID: mdl-32824184

ABSTRACT

The absorption and binding energy of material plays an important role with a large surface area and conductivity for the development of any sensing device. The newly grown 2D nanomaterials like black phosphorus transition metal dichalcogenides (TMDCs) or graphene have excellent properties for sensing devices' fabrication. This paper summarizes the progress in the area of the 2D nanomaterial-based surface plasmon resonance (SPR) sensor during last decade. The paper also focuses on the structure of Kretschmann configuration, the sensing principle of SPR, its characteristic parameters, application in various fields, and some important recent works related to SPR sensors have also been discussed, based on the present and future scope of this field. The present paper provides a platform for researchers to work in the field of 2D nanomaterial-based SPR sensors.

8.
Microb Drug Resist ; 26(8): 971-975, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32101083

ABSTRACT

Aim: To investigate the phenotypic and genotypic profile of multidrug-resistant (MDR) Mycobacterium tuberculosis (MTB) clinical isolates with reference to second-line injectable drugs (SLIDs). Methods: A total of 110 MTB isolates, recovered consecutively from confirmed MDR-TB patients between March and June 2016, were included in this study. Phenotypic drug susceptibility testing against SLIDs (Kanamycin, Amikacin, and Capreomycin) and Ofloxacin (OFX) was performed using the MGIT 960 system. For genotypic analysis, SLID/(s) resistant (n = 13) and susceptible isolates (n = 26) were subjected to PCR and DNA sequencing for rrs, eis (promoter region), and tlyA loci of MTB. Furthermore, the identified genetic mutations were analyzed with respect to its significance in detecting phenotypic resistance. Result: Among the 110 analyzed isolates, phenotypic resistance to OFX, SLIDs, and to both was 59.1%, 11.8%, and 10.0%, respectively. Out of a total 13 SLID/(s) resistant isolates, 10 had mutations (including two novel mutations) in one or more of the targeted genes. Only one SLID susceptible MTB isolate showed mutation in the targeted region. In SLID resistant isolates, most frequent mutation detected was C-12T under eis promoter region (46.1%). Conclusion: Mutations in rrs, eis, and tly A loci together are important in predicting SLID resistance in MTB isolates. Future molecular epidemiology studies are needed to have more insight into frequency and clinical relevance of novel mutations identified in this study.


Subject(s)
Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Multiple, Bacterial/genetics , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/genetics , Genes, Bacterial , Genotype , Humans , India , Microbial Sensitivity Tests , Phenotype , Promoter Regions, Genetic , Sequence Analysis, DNA
11.
Indian J Exp Biol ; 54(4): 229-36, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27295919

ABSTRACT

Rapid and correct diagnosis is crucial for the management of multidrug resistance (MDR) in Mycobacterium tuberculosis (MTB). The present study aims at rapid diagnosis for identification of multidrug resistance tuberculosis (MDR-TB) using real-time PCR. FRET hybridization probes targeting most prominent four selected codons for rpoB526 and 531 and for katG314 and 315 genes were designed and evaluated on 143 clinical MTB isolates and paired sputa for rapid detection of MDR-TB. The results of real-time PCR were compared with gold standard L-J proportion method and further validated by DNA sequencing. Of the 143 MTB positive cultures, 85 and 58 isolates were found to be 'MDR' and 'pan susceptible', respectively by proportion L-J method. The sensitivity of real-time PCR for the detection of rifampicin (RIF) and isoniazid (INH) were 85.88 and 94.11%, respectively, and the specificity of method was found to be 98.27%. DNA sequencing of 31 MTB isolates having distinct melting temperature (Tm) as compared to the standard drug susceptible H37Rv strain showed 100% concordance with real-time PCR results. DNA sequencing revealed the mutations at Ser531Leu, His526Asp of rpoB gene and Ser315Thr, Thr314Pro of katG gene in RIF and INH resistance cases. This real-time PCR assay that targets limited number of loci in a selected range ensures direct and rapid detection of MDR-TB in Indian settings. However, future studies for revalidation as well as refinement are required to break the limitations of MDR-TB detection.


Subject(s)
Real-Time Polymerase Chain Reaction/methods , Tuberculosis, Multidrug-Resistant/diagnosis , Antitubercular Agents/pharmacology , DNA, Bacterial/genetics , Fluorescence Resonance Energy Transfer , Humans , Isoniazid/pharmacology , Microbial Sensitivity Tests , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Rifampin/pharmacology , Sensitivity and Specificity
12.
Biomed Res Int ; 2015: 983978, 2015.
Article in English | MEDLINE | ID: mdl-25945351

ABSTRACT

A total of 355 cows were sampled (serum, n = 315; faeces, n = 355; milk, n = 209) from dairy farms located in the Punjab state of India. Faeces and serum/milk samples were screened by acid fast staining and "indigenous ELISA," respectively. IS900 PCR was used to screen faeces and milk samples. Bio-load of MAP in dairy cows was 36.9, 15.6, 16.3, and 14.4%, using microscopy, serum ELISA, milk ELISA and milk PCR, respectively. Estimated kappa values between different test combinations: serum and milk ELISA, faecal microscopy and faecal PCR, milk ELISA and milk PCR, faecal PCR and serum ELISA were 0.325, 0.241, 0.682, and 0.677, respectively. Estimation of the relative sensitivity and specificity of different tests in the present study indicated that "serum ELISA" and "milk ELISA" were good screening tests, add "milk PCR" was "confirmatory test" for MAP infection. Combination of milk ELISA with milk PCR may be adopted as a model strategy for screening and diagnosis of JD in lactating/dairy cattle herds in Indian conditions.


Subject(s)
Cattle Diseases/genetics , Mycobacterium avium subsp. paratuberculosis/isolation & purification , Paratuberculosis/diagnosis , Agriculture , Animals , Cattle , Cattle Diseases/microbiology , Dairying , Feces/microbiology , Female , Humans , India , Lactation , Milk/microbiology , Mycobacterium avium subsp. paratuberculosis/genetics , Mycobacterium avium subsp. paratuberculosis/pathogenicity , Paratuberculosis/microbiology
13.
Indian J Med Res ; 141(1): 55-61, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25857495

ABSTRACT

BACKGROUND & OBJECTIVES: Of the three major genotypes of Mycobacterium avium subspecies paratuberculosis (MAP), 'Bison type' is most prevalent genotype in the domestic livestock species of the country, and has also been recovered from patients suffering from Crohn's disease. Recently, a new assay based on IS1311 locus 2 PCR- restriction endonuclease analysis (REA) was designed to distinguish between 'Indian Bison type' and non-Indian genotypes. The present study investigated discriminatory potential of this new assay while screening of a panel of MAP isolates of diverse genotypes and from different geographical regions. METHODS: A total of 53 mycobacterial isolates (41 MAP and 12 mycobacterium other than MAP), three MAP genomic DNA and 36 MAP positive faecal DNA samples from different livestock species (cattle, buffaloes, goat, sheep and bison) and geographical regions (India, Canada, USA, Spain and Portugal) were included in the study. The extracted DNA samples (n=92) were analyzed for the presence of MAP specific sequences (IS900, ISMav 2 and HspX) using PCR. DNA samples were further subjected to genotype differentiation using IS1311 PCR-REA and IS1311 L2 PCR-REA methods. RESULTS: All the DNA samples (except DNA from non-MAP mycobacterial isolates) were positive for all the three MAP specific sequences based PCRs. IS1311 PCR-REA showed that MAP DNA samples of Indian origin belonged to 'Bison type'. Whereas, of the total 19 non-Indian MAP DNA samples, 2, 15 and 2 were genotyped as 'Bison type', 'Cattle type' and 'Sheep type', respectively. IS1311 L2 PCR-REA method showed different restriction profiles of 'Bison type' genotype as compared to non-Indian DNA samples. INTERPRETATION & CONCLUSIONS: IS1311 L2 PCR-REA method successfully discriminated 'Indian Bison type' from other non-Indian genotypes and showed potential to be future epidemiological tool and for genotyping of MAP isolates.


Subject(s)
Genes, Bacterial , Mycobacterium avium subsp. paratuberculosis/classification , Polymerase Chain Reaction/methods , Animals , India , Mycobacterium avium subsp. paratuberculosis/genetics
14.
PLoS One ; 10(4): e0122979, 2015.
Article in English | MEDLINE | ID: mdl-25853708

ABSTRACT

The tubercle complex consists of closely related mycobacterium species which appear to be variants of a single species. Comparative genome analysis of different strains could provide useful clues and insights into the genetic diversity of the species. We integrated genome assemblies of 96 strains from Mycobacterium tuberculosis complex (MTBC), which included 8 Indian clinical isolates sequenced and assembled in this study, to understand its pangenome architecture. We predicted genes for all the 96 strains and clustered their respective CDSs into homologous gene clusters (HGCs) to reveal a hard-core, soft-core and accessory genome component of MTBC. The hard-core (HGCs shared amongst 100% of the strains) was comprised of 2,066 gene clusters whereas the soft-core (HGCs shared amongst at least 95% of the strains) comprised of 3,374 gene clusters. The change in the core and accessory genome components when observed as a function of their size revealed that MTBC has an open pangenome. We identified 74 HGCs that were absent from reference strains H37Rv and H37Ra but were present in most of clinical isolates. We report PCR validation on 9 candidate genes depicting 7 genes completely absent from H37Rv and H37Ra whereas 2 genes shared partial homology with them accounting to probable insertion and deletion events. The pangenome approach is a promising tool for studying strain specific genetic differences occurring within species. We also suggest that since selecting appropriate target genes for typing purposes requires the expected target gene be present in all isolates being typed, therefore estimating the core-component of the species becomes a subject of prime importance.


Subject(s)
Genetic Variation , Mycobacterium tuberculosis/genetics , Phylogeny , Tuberculosis/genetics , Base Sequence , Comparative Genomic Hybridization , DNA, Bacterial/genetics , Genome, Bacterial , Humans , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/pathogenicity , Tuberculosis/microbiology , Tuberculosis/pathology
15.
Indian J Exp Biol ; 53(1): 16-24, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25675707

ABSTRACT

'Indigenous vaccine' prepared from 'Indian Bison Type' a native bio-type of Mycobacterium avium subspecies paratuberculosis strain 'S5' of goat origin (goat based) was evaluated in indigenous cattle herds located in gaushalas (cow shelters), endemic for Bovine Johne's disease. Cows (893) were randomly divided into vaccinated (702 = 626 adults + 76 calves) and control (191 = 173 adults + 18 calves) groups. Response to vaccination was evaluated on the basis of health (mortality, morbidity), productivity (growth rate, reproductive performance, total milk yield), immunological parameters (LTT, ELISA titer), survivability of animals naturally infected with MAP, bacterimia (by specific blood PCR), seroconversion (by indigenous ELISA) and status of shedding of MAP in feces (by microscopy) in the two groups before and after vaccination. Reduction in MAP shedding [to the extent of 100% in Herd A; and from 82.1% (0 DPV) to 10.7% (270 DPV) in Herd C] was the major finding in vaccinated cows. Whereas, the control group cows have shown no improvement. As the first indicator of vaccine efficacy, MAP bacilli disappeared from the blood circulation as early as 15 days post vaccination, however, peak titers were achieved around 90 DPV. Peak titers initially declined slightly but were maintained later throughout the study period. Control animals did not show any pattern in antibody titers. Mortality was low in vaccinated as compared to the control groups. Vaccination of endemically infected native cattle herds with inactivated whole-cell bacterin of novel 'Indian Bison Type' bio-type of goat origin strain 'S5' effectively restored health and productivity and reduced clinical BJD. Application of goat based 'indigenous vaccine' for therapeutic management of BJD in native cattle herds (gaushalas) is the first of its kind.


Subject(s)
Bacterial Vaccines/administration & dosage , Mycobacterium avium subsp. paratuberculosis/immunology , Paratuberculosis/prevention & control , Animals , Antibodies, Bacterial/biosynthesis , Cattle , Endemic Diseases , Goats , Immunity, Cellular , Paratuberculosis/immunology , Polymerase Chain Reaction
16.
Genome Announc ; 1(6)2013 Nov 21.
Article in English | MEDLINE | ID: mdl-24265488

ABSTRACT

We describe the genome sequencing and analysis of a clinical isolate of the multidrug-resistant Mycobacterium tuberculosis Uganda I genotype (OSDD515) from India.

17.
Genome Announc ; 1(6)2013 Nov 21.
Article in English | MEDLINE | ID: mdl-24265496

ABSTRACT

We describe the genome sequencing and analysis of a multidrug-resistant (MDR) clinical isolate of Mycobacterium tuberculosis, strain OSDD105 from India, belonging to a novel spoligotype.

18.
Genome Announc ; 1(4)2013 Aug 01.
Article in English | MEDLINE | ID: mdl-23908284

ABSTRACT

We describe the genome sequencing and analysis of a clinical isolate of Mycobacterium tuberculosis East African Indian (EAI) strain OSDD271 from India.

19.
Genome Announc ; 1(1)2013 Jan.
Article in English | MEDLINE | ID: mdl-23469332

ABSTRACT

We report the 4.79-Mb genome sequence of the "Indian Bison Type" biotype of Mycobacterium avium subsp. paratuberculosis strain S5, isolated from a terminally sick Jamunapari goat at the CIRG (Central Institute for Research on Goats) farm in India. This draft genome will help in studying novelties of this biotype, which is widely distributed in animals and human beings in India.

20.
J Biomed Sci ; 20: 14, 2013 Feb 28.
Article in English | MEDLINE | ID: mdl-23448104

ABSTRACT

MicroRNAs (miRNAs) are evolutionarily conserved, naturally abundant, small, regulatory non-coding RNAs that inhibit gene expression at the post-transcriptional level in a sequence-specific manner. Due to involvement in a broad range of biological processes and diseases, miRNAs are now commanding considerable attention. Although much of the focus has been on the role of miRNAs in different types of cancer, recent evidence also points to a critical role of miRNAs in infectious disease, including those of bacterial origin. Now, miRNAs research is exploring rapidly as a new thrust area of biomedical research with relevance to deadly bacterial diseases like Tuberculosis (caused by Mycobacterium tuberculosis). The purpose of this review is to highlight the current developments in area of miRNAs regulation in Mycobacterial diseases; and how this might influence the diagnosis, understanding of disease biology, control and management in the future.


Subject(s)
Gene Expression Regulation , MicroRNAs/genetics , Mycobacterium tuberculosis/genetics , Tuberculosis/genetics , Humans , MicroRNAs/biosynthesis , MicroRNAs/metabolism , Mycobacterium tuberculosis/pathogenicity , RNA Interference , Tuberculosis/microbiology , Tuberculosis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...